PUBLIC COMPANY
saveCity of Hope
updated 3mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology2 co-mentions · 2 sources
- tagAML1 co-mentions · 1 sources
- drugMETHOTREXATE1 co-mentions · 1 sources
- tagType 1 Diabetes1 co-mentions · 1 sources
- tagType 2 Diabetes1 co-mentions · 1 sources
- tagVaccine1 co-mentions · 1 sources
- tagDLBCL1 co-mentions · 1 sources
- tagEndocrinology & Metabolism1 co-mentions · 1 sources
pipeline
2
marketed
0
phase 3
0
catalysts ytd
9
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.biopharma_dive · 4mo ago
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.biopharma_dive · 4mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 4mo ago
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 4mo ago
comments(0)
5-min edit window · permanent after that